Optimi Health announces the completion of its previously announced lab expansion for its Princeton, British Columbia facility.
Exploring the companies and themes that make up this emerging and exciting new sector
COMPASS Pathways plc announces first quarter 2022 financial results and business highlights
Compass Pathways reports its Q1 for 2022. Net loss of $21.2 million on increased R&D expenses. Cash position of $243.7 million.
Psychedelic Medicine: The New Frontier In Healthcare, The Big Opportunity In Biopharma
A plethora of drug R&D opportunities. A multitude of badly under-served healthcare treatment markets. A medical "miracle"; an investment pot of gold.
New York Lawmakers Discuss Competing Psychedelics Reform Bills Ahead Of Key Deadline
With just a month left before the end of New York’s legislative session, lawmakers sponsoring differing psychedelics reform legislation recently participated in a discussion on the path forward for psilocybin in the Empire State.
PharmaTher Announces Grant of U.S. Patent on Formulation and Production Process of Ketamine and Ketamine Analogs
Pharmather announces receiving a patent from the USPTO for its "ketamine flow synthesis". Pharmather has exclusive worldwide development and commercial rights to this IP.
Wesana Announces Singular Focus on Drug Development Prompting a Strategic Review of its Clinics and Other Care Delivery Assets
Wesana announces a strategic review of its assets and a decision to focus on drug development.
Optimi Health Granted Amendment To Controlled Substances Dealer’s Licence
Optimi Health announces receiving amendment to Health Canada's Dealer's License that will allow expand cultivation and research use of psilocybin and psilocin.
Ketamine Wellness Centers (KWC) Introduces NAD+ Infusion Therapy
Delic Holdings announces a new health & wellness therapy offered through its Ketamine Wellness Centers mental health clinics.
MYDECINE INNOVATIONS GROUP ANNOUNCES CLOSING UNDER SHARE SUBSCRIPTION AGREEMENT
Mydecine announces raising $1,693,434.60 in addition to gross proceeds of $333,333.35 announced on March 22, 2022.
Wesana Health Reports Q4 2021 Financial Results and Provides Subsequent Period Highlights
Wesana reports its Q4 2021 financial results and announces closing of a financing.
Awakn Life Sciences Reports Fiscal Fourth Quarter and Fiscal Year January 31, 2022, Results
Awakn Life Sciences reports fourth quarter and full-year results for its fiscal year ending January 31, 2022. Annual revenues of CAD$236,037.
Optimi Health Opens Canada’s Largest GMP-Grade Licensed Psilocybin Cultivation Facility
Optimi Health announces the opening of Canada's largest GMP-grade psilocybin cultivation operating, including a 10,000 square foot production facility.